Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers (Q43954071)

28 November 2017

Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers (English)

1 reference

primary biliary cholangitis

28 November 2017

0 references

1 reference

0 references

author name string

Uwe Ritzel

1

1 reference

28 November 2017

Urs Leonhardt

2

1 reference

28 November 2017

Martina Näther

3

1 reference

28 November 2017

Gertrud Schäfer

4

1 reference

28 November 2017

Victor W Armstrong

5

1 reference

28 November 2017

Giuliano Ramadori

6

1 reference

28 November 2017

1 April 2002

1 reference

28 November 2017

Journal of Hepatology

1 reference

28 November 2017

36

1 reference

28 November 2017

454-458

1 reference

28 November 2017

4

1 reference

Primary biliary cirrhosis

28 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900006-5

7 January 2021

Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900006-5

7 January 2021

Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900006-5

7 January 2021

Lipoprotein abnormalities in patients with early primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900006-5

7 January 2021

Hypercholesterolemia in primary biliary cirrhosis is no risk factor for atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900006-5

7 January 2021

Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900006-5

7 January 2021

Primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900006-5

7 January 2021

Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900006-5

7 January 2021

Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in various forms of dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900006-5

7 January 2021

Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900006-5

7 January 2021

Effect of simvastatin on receptor-dependent low density lipoprotein catabolism in normocholesterolemic human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900006-5

7 January 2021

Abnormalities of serum apo A1 containing lipoprotein particles in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900006-5

7 January 2021

Lovastatin added to ursodeoxycholic acid further reduces biliary cholesterol saturation.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900006-5

7 January 2021

Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid: evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900006-5

7 January 2021

NIH conference: Primary biliary cirrhosis: a model autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900006-5

7 January 2021

Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900006-5

7 January 2021

HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900006-5

7 January 2021

Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900006-5

7 January 2021

Menopausal status and risk factors for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900006-5

7 January 2021

Effect of bezafibrate in primary biliary cirrhosis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900006-5

7 January 2021

10.1016/S0168-8278(02)00006-5

Identifiers

DOI

1 reference

release_exrimhpfjzgtdmx7zmwgex3une

28 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/exrimhpfjzgtdmx7zmwgex3une

24 November 2022

mapped directly with Wikidata item

1 reference